Perrigo Company plc Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount
Perrigo Company plc (PRGO) reported Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount of $129.90 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-26.
Financial Statements › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities › Components of Deferred Tax Assets
us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount · last filed 2026-02-26
- Perrigo Company plc valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2025 was $129.90M, a 128.70% increase from fiscal 2024.
- Perrigo Company plc valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2024 was $56.80M, a 35.56% increase from fiscal 2023.
- Perrigo Company plc valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2023 was $41.90M.
- Perrigo Company plc valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2022 was -$56.20M, a 256.55% decline from fiscal 2021.
| Period end | Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount 12 month | Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount 12 month as first filed |
|---|---|---|
| 2025-12-31 | $129.90M 10-K · filed 2026-02-26 | |
| 2024-12-31 | $56.80M 10-K · filed 2026-02-26 | $47.70M 10-K · filed 2025-02-28 |
| 2023-12-31 | $41.90M 10-K · filed 2026-02-26 | $46.40M 10-K · filed 2024-02-27 |
| 2022-12-31 | -$56.20M 10-K · filed 2025-02-28 | |
| 2021-12-31 | $35.90M 10-K · filed 2024-02-27 | -$35.90M 10-K · filed 2022-03-01 |
| 2020-12-31 | -$86.50M 10-K · filed 2021-03-01 | |
| 2019-12-31 | -$56.60M 10-K · filed 2020-02-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |